\
&
Contact us
\
&
Contact us
Published on | 4 years ago
ProgrammesGender equality plans are not an eligibility criterion for the ERC calls from the 2021 Work Programme. This was also clarified in the Information for Applicants for the currently open Starting and Consolidator grants calls (p.17/8).
Panel chairs are published for the 2021 Starting and Consolidator grants calls: Panel Chairs of the ERC Peer Review Panels ERC Starting Grant Panel 2021 and Panel Chairs of the ERC Peer Review Panels ERC Consolidator Grant Panel 2021
Tentative dates for the calls under the 2022 work programme have been published. In addition to a call for Starting, Consolidator and Advanced grants, a call for Synergy grants is included as well as multiple cut-off dates for Proof of concept grants. Please note they are subject to change. Publication of the 2022 work programme is expected in July the earliest.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space Cybersecurity
The EU introduced a new ICT Supply Chain Security Toolbox, providing an EU approach to identify, assess, and mitigate cybersecurity risks across ICT supply chains. The toolbox will help Member States and public and private actors to bolster the security of ICT supply chains in the EU as set out in the revised Cybersecurity Act presented... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
